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In utero aminoglycosides-Induced nephrotoxicity in rat neonates. Preg-
nant Wistar females were treated with gentamicin (G), netilmicin (N) or
amikacin (A) during two periods of pregnancy covering organogenesis
and the beginning of nephrogenesis. Deliveries occurred normally. We
studied functional effects—influence of sex, litter size, diuresis, creat-
mine clearance, 0-kidney concentration, and kidney morphological
alterations—in rat neonates on day 1 of life. After 0 and N, the
creatinine clearance of the neonates was decreased according to the
dosage given to the mother. Whatever the aminoglycoside, kidneys
presented proximal tubular alterations (close to those observed in
adults) at protonic microscopy and, with electron microscopy, some
modifications of distal tubules and of mature and immature glomeruli. It
is concluded that the developing kidney can be altered after treating
pregnant mothers with aminoglycosides. This model of in utero-induced
nephrotoxicity is dose-dependent. Mature and/or immature structures
could be affected. The toxicity of the investigated antibiotics could be
asserted as G N > A.
The effect upon the neonate's kidney of drugs given during
pregnancy is rarely scrutinized [1—8]. Toxicologic studies are
usually considered acceptable when animal reproduction is
possible and leads to apparently normal offspring presenting
normal weaning, growth, and reproductive capability [9, 10].
Teratological defects resulting from the use of modern drugs are
rarely reported and little attention is currently being paid to the
kidney. Nevertheless, it seems logical that a drug having a renal
effect in the mother, and able to cross the placental barrier,
would also have a renal effect in the fetus and/or in the neonate.
Such an effect would probably remain hidden from routine
toxicological studies [11—13].
Due to particularities of the developing kidney [14-17], the
period of drug administration during the pregnancy, and dura-
tion of treatment, this possible fetal renal effect could affect
either developed or developing structures [18]. One of us
reported previously that gentamicin given to pregnant rats leads
to kidney morphological alterations in neonates which pre-
sented a slowing down of the maturation and, moreover, an in
utero-acquired nephrotoxicity [19—21].
The purpose of this study was to investigate the renal
function during this gentamicin nephrotoxicity. In addition, the
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histopathological and functional effects of two widely used
aminoglycosides (netilmicin and amikacin) were studied. In an
attempt to present simultaneous evidence for this in utero-
acquired nephrotoxicity, the gentamicin concentration was
measured in neonate kidneys. Investigations were also con-
ducted on the mother at the time of delivery, but only to be sure
that the observed neonate's status was not an affect of an
eventual maternal renal failure.
Gentamicin was given at three different dosages (25, 50 or 75
mg/kg) in order to search for a possible dose-dependent effect.
The dosage of netilmicin (60 mg/kg) was lower than the more
nephrotoxic dosage of gentamicin (75 mg/kg). The dosage ratio
of netilmicin to amikacin (180 mg/kg) was chosen to obtain
equally potent bactericidal activity [22, 23]. In addition, some
experiments were conducted using a very low dose of gentami-
cm (7.5 mg/kg) or a high dose of amikacin (250 mg/kg). The
nephrotoxicity of these dosages will be discussed later.
Antibiotics were given during two periods of the pregnancy in
each experiment: the organogenesis and the beginning of the
nephrogenesis. They were never administered during the last
two days before delivery.
Methods
General protocol
Constitution of groups. Groups of pregnant and non-pregnant
Wistar rats were used.
The first group of females were mated with males, and day I
of pregnancy was defined as the day that sperm was found in
vaginal smear.
For non-pregnant rats, females were isolated from males,
housed in the laboratory, and treated in the same way as were
pregnant animals.
Treatment. Pregnant and non-pregnant females were then
allocated into sub-groups: control (C), gentamicin 75 mg/kg
(G75), 50 mg/kg (050), 25 mg/kg (G25) or 7.5 mg/kg (G7.5),
netilmicin 60 mg/kg (N), and amikacin 180 mg/kg (A 180) or 250
mg/kg (A250) (Table 1).
Drugs were given during the second week of pregnancy (or of
observation for the non-pregnant groups), on days 7 to 11, and
during the third week on days 14 to 18. Dosages were calculated
each day after determining the body weight and were adminis-
tered by subcutaneous injection between 3:00 and 5:00 p.m.
Commercial preparations of antibiotic solutions were used:
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Table 1. Repartition in groups (pregnant or non-pregnant) and subgroups (treatment)
C G.7.5 G-25 G-50 G-75 N-60 A-180 A-250
Non-pregnant
N 10 8 8 7
D8 body wt g 310.9 8.1 300.9 7.2 299.3 19.4 298.2 12.2
D20 body wt g 371.4 8.6 301.2 11.2 301.0 16.4 300.0 12.0
Pregnant
N 20 3 6 7 28 13 12 5
Allowed to litter 12 3 6 7 18 7 6 5
D8 body wt g 308.5 7.4 295.6 9.7 310.3 7.2 345.1 18.8 314.6 9.5 306.3 11.6 309.4 10.8 293.5 9.0
D20 body wt g 387.1 6.9 360.2 15.2 Not recorded Not recorded 376.9 13.1 365.1 20.7 380.1 16.8 Not recorded
Mean N pups/litter 11.7 0.7 12.0 0.6 12.0 0.9 12.4 2.1 12.2 0.6 11.0 1.5 10.7 0.7 13.4 0.7
N or renal function 98 — 44 44 82 50 41 47
measurements
N of histopatholog- 6 3 8 9 9 6 6 6
ical examinations
Body weights of females on D8 and D20 of gestation or observation, mean number of pups per litter and number of pups which had renal function
measurements and histopathological examinations are in the text.
gentamicin (Gentalline, Laboratoires Unicet), netilmicin (Ne-
tromicine, Laboratoires Unicet) and amikacin (Amiklin, Labo-
ratoires Bristol).
On the same days, pregnant and non-pregnant C females
were given a similar volume of saline serum (0.7%) by the same
method.
Selection of litters and maternal biology. In this strain, birth
normally occurs on the afternoon of the twenty-second day of
gestation; the day after is considered day I of life.
Several mothers taken at random from each sub-group were
sacrificed shortly after the birth, together with all the non-
pregnant females. Blood samples were taken by cardiac punc-
ture and centrifuged. Other mothers were allowed to litter
(Table 1). Plasmas were analyzed for Na and K using a flame
emission spectrophotometer (Instrument Laboratory IL 243,
Paris, France), for BUN and creatinine with an automatic
analyzer (ABA 100, Laboratoires Abbot, Paris, France), and
for protein with a refractometer.
Renal function measurements in neonates
On day 1 of life, the neonates were subjected to a basal
clearance evaluation following techniques described by Kay-
lock and Gray [24, 251 and Kaviock et al [26, 27]. After the
bladders had been voided, the pups were kept for three hours in
a specially designed device. They were housed separately in
beakers placed in a water bath to keep the surface of the
bedding at 32 to 34°C in an humidity saturated atmosphere. At
the end of the period, the bladders were voided again and urine
quantitatively collected in calibrated tubes. The pups were
weighed. The kidneys were quickly removed by opening the
flank, then trunk blood was collected into Serum Separator
tubes (Becton Dickinson) after decapitation. Due to the small
amount of blood samples, only creatinine and protein levels
were measured.
Diuresis was stated per hour per gram of body weight.
Creatinine clearance (Car) and FE H2O were calculated using
the standard formula.
Pathology
Females. In several treated females, pregnant and non-
pregnant, the kidneys were removed and a routine pathological
examination (Table 1) was performed to verily the presence and
the intensity of well known features of aminoglycoside nephro-
toxicity [28, 291.
Neonates. Fifty-three random neonates from 64 litters were
histopathologically examined at the end of the clearance period
prior to decapitation (Table 1).
After opening the flank, glutaraldehyde was immediately
dripped on the left kidney, which was then transferred into vials
containing glutaraldehyde and cut into 1 mm3 blocks. These
fragments were fixed in 2% glutaraldehyde in 0.2 M cacodylate
buffer (pH 7.4) for two hours. The fragments were then rinsed
in saccharose and post-fixed for one hour in 1% osmium oxyde.
After dehydration in graded ethanol solutions, tissue blocks
were embedded in Epon 812. Semithin sections (1 ) were
stained with toluidine blue; ultrathin sections were stained with
uranyl acetate and lead citrate (LKB ultrastainer) and examined
at 60 KV in a Philips EM 301 electron microscope.
The right kidney was removed without dripping and trans-
ferred into fixative (Dubosq-Brazil) for 24 hours. After embed-
ding in Paraplast, it was sliced into 2 sm cuts and then stained
with hematotoxylin, eosin, light green trichome, Schiff period-
ic-acid and silver methenamine.
Kidney concentration of gentamicin
Renal gentamicin concentrations were assayed microbiologi-
cally by an Agar diffusion technique using bacillus subtillis
ATCC 6633 as a test organism. The detection limit was 0.049
jg/m1. Each kidney was homogenized individually in sterile
0.01 M phosphate buffer pH 8.0 (1:10 wt/vol) using a kontess
conical sintered, glass tissue grinder. Each determination was
done in triplicate at two dilutions. Results are expressed as g
of gentamicin per gram of wet tissue.
Statistics
Results are given as means SEM. For each criterium, a
multifactorial analysis was performed using SPSS-X Informa-
tion System (Statistical Package for Social Sciences) with a
DPS-8 BULL system (Multics). When a significant difference in
a group was found for one or more treatments a paired t-test
was applied.
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Pregnant vs. control-pregnant or non-pregnant vs. control-non-pregnant: P < 0.05; b P < 0.001
Pregnant versus non-pregnant: "P < 0.05; d P < 0.001
Table 3. Body weights and renal functions of rat neonates on day I of life after mothers have been given
mg/kg/day), netilmicin (N, 60 mg/kg/day), or amikacin (A, 180, 250 mg/kg/day) on days 7 to 11
saline (C), gentamicin (G, 25, 50, 75
and 14 to 18 of gestation
C G-25 G-50 G-75 N-60 A-180 A-250
N of pups 98 44 44 82 50
Body wt. g 6.756 0.097 7.276 0.134" 6.747 0.089 6.332 0.085" 7.067 0.0928
Diuresis 2.475 0.093 2.711 0.172 2.379 0.119 2.111 0085b 2.229 0.111
41 47
7.081 0. 1258 6.272 0.090"
2.653 0.134 1.999 0.122"
uJ/g/hr
Ut,. mg/liter 155.8 9.2 122.5 8.3" 142.1 12.0 135.7 7.5 146.1 7.4
UcVpg/g/hr 313.2 8.1 303.7 12.8 290.7 11.3 254.5 10.8" 305.7 11.1
PCr mg/liter 4.89 0.07 4.66 0.12 5.22 0.12 5.64 0.15" 5.73 0.14"
Ccrpi/g/hr 65.7 2.1 65.3 3.1 55.8 1.9" 48.3 2.3" 55,3 2.6"U/Pc 33.0 2.3 27.0 2.18 26.9 2.18 24.9 1.5" 26.7 1.78
FE H20 % 4.25 0.25 4.52 0.28 4.40 0.23 5.28 0.35 4.52 0.31
Proteins g/liter 23.5 0.4 21.6 0.5 21.7 0.3 22.9 0.5 25.1 0.7
123.2 10.78 206.8 14.9"
300.7 21.9 348.2 17.68
4.59 0,26 5.10 0.18
64.2 4.8 69.5 2.7
27.1 2.7 40.0 2.78
4.78 0.51 3.00 0.21
24.8 0.8 20.9 0.6
Results as mean SEM, vs. C: "P < 0.05, b < 0.01, <0.001
Results
Females
Blood biology. Results are reported in Table 2. Pregnant rats
presented no acute renal failure after gentamicin, netilniicin, or
amikacin. Non-pregnant rats presented a hypoproteinemia after
either G, N, or A.
Pathology. All animals presented various grades of kidney
alterations; however, the degree was rarely severe in pregnant
rats. These aspects are similar to the currently known patho-
logical features of experimental nephrotoxicity [28, 291.
Neonates
Functional effects. The sex did not affect the results whatever
the parameter or the group (N males, 205; females, 201). No
significant difference was noted in the mean number of pups in
each group (Table 1).
With high dosages of gentamicin (Table 3), G75 pups were
smaller than C neonates (P < 0.001) Creatinine clearance was
lower (P < 0.001), due to a lower diuresis (P < 0.01), a lower
urine creatinine concentration (NS) and a higher blood creati
nine concentration (P < 0.001), (Fig. 1).
In intermediate dosages of gentamicin, U/P creatinine ratios
were lower in G25 (P < 0.05) and G50 (P < 0.05) than in C pups.
ifowever. creatinine clearance was unaffected in G25, but
BW U P Ccr U/P Fel-120
Fig. 1. Effects on neonates of gentamicin given to the pregnant
mother. Bars represent prenatally exposed neonates on the right hand
and controls on the left hand. Variations are in percentage.
lower in G50 (P < 0.01). The latter was intermediate between C
or G25 and G75 values (Fig. 2).
Creatinine clearance was lower in N60 taking netilmicin than
in C group (P < 0.01), with a lower U/P creatinine ratio (P <
0.05) and a higher PC, (P < 0.001). These values were close to
those of the G50.
A180 pups taking amikacin presented a lower creatinine urine
















C G25 G50 G75 N60 A180 A250
Fig. 2. Creatinine clearance in the rat neonates on day I of life after
mothers have been treated with varying doses of different ami-
noglycosides
As compared to the C group, A250 neonates were smaller
(P < 0.001); they had a lower diuresis (P < 0.001) and a higher
creatinine urine concentration (P < 0.001), creatinine excretion
(P < 0.05) and U/P creatinine ratio (P < 0.05).
Pathology. Proximal tubules of mature nephrons (fully func-
tional nephrons of the juxtamedullary area, standard sections of
2r) exhibited degenerative alterations which varied in severity
and extent. Cells were swollen, cytoplasm was cloudy, and
there were numerous vacuoles and often PAS-positive inclu-
sions. Sometimes an atrophy of the brush border, an epithelial
flattening and/or an enlargement of lumen were observed.
Necrosis was rarely present. There was no evidence of
regeneration and mitoses in proximal tubules but mitoses were
very numerous in collecting ducts and undifferentiated neph-
rons. Glomeruli, distal tubules and collecting ducts appeared
normal.
Electron microscopy showed that lesions were of the same
type whatever the drug, but most of them were dependent on
the dosage.
Alterations of proximal tubules were mild, focal, seen only in
mature nephrons, and were mainly modifications of the lysoso-
ma! system (increase in number and size of phagosomes and
lysosomes, cytosome coalescence with autophagic vacuoles,
Figs. 3 and 4). Lysosomes were heterogeneous: clear and
granulated, dense with various opaque areas, or figuring large
and empty vacuoles. Myelin figures or myeloid bodies were
observed in lysosomes, in mitochondria, free in the hyaloplasm,
or in the tubular lumen. These figures were unusual in the
control's kidneys, but they were very numerous after aminogly-
cosides whatever the drug, increasing according to the dosage.
Mitochondrial modifications were rare and usually present as
coalescence with lysosomes. The brush border was atrophic
and it disappeared in several cases where cells presented a
protruding apical pole, poor in organites (Fig. 5). Focal necrosis
and cell desquamation were exceptional.
Mature or immature glomeruli presented, depending on the
dosage, with myelin figures and autophagic vacuoles (Figs. 6
and 7). In differentiated distal tubules myeloid bodies were also
present.
Table 4. Morphological comparison of 35 rat neonates prenatally
exposed to aminoglycosides
Total marks
for I kidney N 0—1 2—3 4—S 6—7 8—9 10—11 12—14
G7.5 3 2 1
G25 8 7 1
G50 7 2 4 1
G75 3 1 1 1
N60 6 5 1
A180 6 2 3 1
A250 2 1 1
For one kidney, seven parameters were graded and added up.
Repartition of the sums according to the treatment.
Since the features of morphological effects of aminoglyco-
sides were not very different, we tried to quantify them in order
to assess possible differences.
Using semithin sections, seven parameters were investigated:
lumen dilations, altered brush borders, apical protrusion, clear
vacuoles, lysosomal hypertrophy, luminal casts, and myeloid
bodies. They were graded: 0, absence; I, moderate presence; 2,
sizable presence. For each kidney, the seven marks were added
up, and the sums were then alloted to seven possible classes.
Table 4 shows the number of occurrences in each class.
Mult(factorial analysis. The Bonferoni test was used to
compare groups one by one with each other for nine parameters
(Table 5). Differences were considered significant if P < 0.05. A
progression was noted in G groups: G75 presented four differ-
ences compared to C, three to G25 and one to G50. The widest
range of differences was observed in A250. N60 was close to
G50. A180 was close to G25 and G50 but presented no differ-
ence compared to C. Creatinine clearance was different when C
group was compared to G50, G75 or N60, but not when
compared to G25 or A groups.
Kidney concentration of gentamicin. Results are reported in
Table 6.
Discussion
Aminoglycoside nephrotoxicity has been demonstrated to
follow an almost predictable clinical and functional course in
human and animal studies [30—351, associated with a reproduc-
ible sequence of ultrastructural changes in renal tubular cells
[28, 29, 36—39] and directly related to an accumulation of
aminoglycosides within the renal cortex [31, 40, 41]. Our
findings are consistent with the main aspects of this toxicity.
The dosages of aminoglycosides given to the rats seem very
high compared to those used in humans; however, when they
are compared with body surface area, the differences are less
prominent, and are close to differences in GFR/BSA. More-
over, while the size of the nephron is marginally smaller in the
rat than in man, when expressed by grams of body weight the
number of nephrons is about tenfold in the rat, suggesting a
larger reabsorption area and greater GFR [42—43]. In the same
way, differences of sensitivity have been reported depending on
the rat strain or on subpopulations in the same strain [44].
The originality of this model is that the animal suffering this
toxicity has not received the drugs directly, but from the mother
through the placenta, and that the altered kidney is still imma-
ture, presenting both differentiated and undifferentiated struc-
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Fig. 3. G50; proximal tubules showing numerous
cells with microvacuola (arrows). (Semi-thin,
Toluidine, x420)
Fig. 4. G50; ultrastructural aspect of
degenerative lesions seen in Figure 3.
(Uranyl-lead, x 6230)
tures [17]. In previous studies the kidneys of infants seemed to
be less vulnerable, and aminoglycosides administered during
pregnancy were never shown to be nephrotoxic for the fetus [3,
9—13, 45]. Moreover, this therapy has been recommended for
treatment of intra-uterine infections [46]. Indeed, an acquired
insensitivity of new cells of the proximal tubules after necrosis
to further gentamicin administration has been reported [47], and
a less severe degree of sensitivity of the immature kidney was
found in the rabbit [48] and in the rat [491. However, Von
Husstedt et a! claimed that gentamicin could be dangerous for
the fetus when given to pregnant women [50], and the kidneys
of neonates or infants could be altered after aminoglycosides
were given directly to the subject either clinically [5 1—53] or
experimentally [18, 21, 54]. Our results demonstrate a nephro-
toxicity in the neonates after aminoglycosides have been given
to the mother.
Uremic women or females in experimental uremia give birth
to neonates with an impaired development [551. In our study,
the drug dosages used and the timing of the injections were not
followed by a significant rise of creatinemia or BUN in pregnant
females on the day of delivery. Moreover, the small modifica-
tions noted were less noticeable in the pregnant than in the
non-pregnant groups. This can probably be explained by the
adaptation of the rat kidneys to pregnancy and the increase of
GFR [56-581.
Gentamicin is present in the neonate's kidneys in a concen-
I 
I 
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Fig. 5. N60 proximal tubule; slight lysosomial
hypertrophy, protruding apical poles, focal
atrophy of brush borders. (Uranyl-lead,
x5020)
Fig. 6. A250; autophagic vacuoles seen in
epithelial cells of immature glomeruli.
(Uranyl-lead, xli, 160)
tration which seems to be relatively independent of the dosage
given to the mothers, and lower than that usually reported in
adults [40, 411. This is probably explained by one or more of the
following factors: 1) The neonatal rat kidney is not mature for
the first 12 to 15 days of life; thus the kidney weight corresponds
to both mature and immature structures. 2) For gentamicin to
be incorporated in proximal tubular cells, it needs to be filtered
and then absorbed through the brush border [31, 58]. Therefore
gentamicin could reach the tubular cells only in fully differen-
tiated nephrons. 3) The total amount of the drug is partly
excreted and partly incorporated into the tissues of the mother.
Only a small portion crosses the placental barrier and is then
diluted into several feto-placental units.
Pathology shows that aminoglycosides can alter the glomeruli
whatever the age of differentiation. Nevertheless tubular alter-
ations are clearly seen only in differentiated nephrons, compa-
rable mainly to those reported either in adults [28, 29, 39, 59] or
in neonates [18]. The toxicity of the three aminoglycosides
cannot be distinguished; morphological effects are only depen-
dent on the dosage, and very small modifications are even seen
after the very low dosage of gentamicin (Table 4, Fig. 7).
A progressive alteration of the creatinine clearance is noted
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Fig. 7. G7.5 proximal tubule; lysosomial coa-
lescence, myeloid bodies in lysoso,nes, mf to-
chondria and lumen, (Uranyl-lead, x 14,700)
Table 5. Difference between groups (Bonferoni tests)
Groups were compared one by one with each other. Nine parameters
were used: body wt, diuresis, FE H20, plasma proteins level, and
creatinine: urinary concentration, excretion, plasma level, clearance
and U/P ratio. The lower triangle shows the number of differing
parameters (shading is proportional to the difference). The upper
triangle shows the only cases where creatinine clearance (C) and plasma
level (P) were significantly different.
according to the dose of gentamicin. The effect of the 60 mg
dosage of netilmicin is close to that of the 50 mg dose of
gentamicin, in agreement with the equivalent nephrotoxicity
generally reported for these two atninoglycosides.
The low dosage of gentamicin (025) is not followed by a
modification of the creatinine clearance. We are inclined to
think that the G25 toxicity is equivalent to a low or a mild
aminoglycoside nephrotoxicity in humans, while G50, G75 and
N60 dosages are responsible for damages too severe to induce
polyuria, but not severe enough to produce oliguria.
The effects of amikacin are not very marked. The Al80 group
shows no decrease of the clearance, this dose is considered to
have a bactericidal activity equipotent to the 60 mg dose of
netilmicin [22, 23]. Surprisingly the A250 group presents a
normal clearance, resulting from a very high urinary concen-
tration of creatinine, despite a significant fall in diuresis. We
could speculate that these animals have had poorer functions in
Table 6. Gentamicin concentration in kidneys of neonates on
day I of life
0-25 0-50 G-75
Nof litters 1 2 2
N of pups 5 8/8 6/7
Gentamicin concen- 1.1540 0.939/0.9597 0.9611/2.053
tration /Lg/g
SEM 0.0587 0.047/0.053 0.0408/0.1237
Mothers have been given 25, 50 or 75 mg/kg of gentamicin, Mean
values for each litter expressed in g of gentamicin per g of wet kidney
wt SEM
utero with some improvement 48 hours after stopping the drug.
Thus the apparently normal GFR may be the result of a
"washing out" of previously increased plasma values. It could
also result from a tubular leakage; pathology gives no evidence
in favor of or against this hypothesis. In this case the creatinine
clearance might not be a good index of GFR.
Thus the progression of functional alterations, according to
the dosages, is comparable to the progression of morphological
modifications for G and N. Taking into account results in
graded comparisons (Table 4), morphological aspects and func-
tional performances, the toxicity of the three investigated
aminoglycosides could be asserted as follows: gentamicin
netilmicin> amikacin. This rank order for toxicity is different
from that observed in adult animals 160, 611.
In conclusion, pathological and functional findings demon-
strate that the developing kidney (male or female) can be altered
after treatment of the pregnant mother with aminoglycosides.
This in utero nephrotoxicity raises the question of the quality of
the future maturation and degree of recovery, and needs further
investigation.
Such an experimental model is strongly dose-dependent and
moderately drug-dependent. it includes a broad field of inves-
tigation because many of the different kidney functions of the
rat neonate have just developed or are still developing, and the
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quality of the final adult kidney could be threatened by in utero
exposure to drugs.
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